374Water Appoints Bradley R. Freels to Board of Directors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 05 2026
0mins
Should l Buy SCWO?
374Water announced the appointment of Bradley R. Freels to the company's Board of Directors, effective January 5, 2026. Freels is a veteran real estate investor, developer and serial entrepreneur. In his current role as Chairman and CEO of Midway, a privately owned real estate investment, development, and construction firm in Houston, Texas he has successfully built a highly respected business that has played a positive impact in the Houston market and across several leading US metro markets
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SCWO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SCWO
About SCWO
374Water Inc. is a global industrial technology and services company. The Company provides solutions to global organic waste destruction/treatment and waste management issues within the municipal, federal, and industrial markets. The Company has developed AirSCWO, a proprietary waste destruction/treatment system which harnesses the power of supercritical water oxidation (SCWO). AirSCWO leverages the properties of water in its supercritical phase (above 374 C and above a barometric pressure of 221 Bar). The supercritical phase of water has properties, which when combined with air, destroys waste by oxidizing organic matter and yielding recoverable energy, minerals, and water. Its AirSCWO technology has treated a variety of non-hazardous and hazardous solid and liquid organic wastes. Its technology can process solid wastes, which can be pre-processed into slurries for treatment, including wastewater sludges and biosolids, spent granular activated carbon, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
374Water Regains Nasdaq Compliance with Minimum Bid Price Requirement
- Compliance Restoration: 374Water has received notification from Nasdaq confirming its compliance with the minimum bid price requirement, indicating that the company's compliance issues are resolved, allowing its stock to continue trading on the Nasdaq Capital Market.
- Price Achievement: The company successfully maintained a closing bid price of $1.00 or more for at least 10 consecutive trading days as of January 9, 2026, meeting Nasdaq's listing rules and avoiding potential delisting risks.
- Historical Context: Previously, 374Water received a notification on January 15, 2025, for failing to maintain the minimum bid price over 30 consecutive trading days, and this restoration signifies the stabilization of the company's stock price.
- Market Impact: This compliance restoration not only boosts investor confidence but may also attract more institutional investors, further enhancing the company's market performance and financing capabilities.
See More
374Water (SCWO) Regains Nasdaq Compliance with 10-Day Bid Price Above $1
- Compliance Regained: 374Water announced it has regained compliance with Nasdaq's minimum bid price requirement, as its shares maintained a closing bid price above $1.00 for 10 consecutive trading days, indicating stability and market confidence.
- Continued Trading: Nasdaq confirmed the company meets Listing Rule 5550(a)(2) and has closed the matter, ensuring that SCWO shares will continue trading on the Nasdaq Capital Market, which enhances investor confidence in its future performance.
- Historical Context: 374Water was previously notified in January 2025 for non-compliance after its shares traded below $1.00 for 30 consecutive business days, and regaining compliance marks a significant recovery for the company in the market.
- Market Reaction: Despite SCWO's stock price dropping 2.32% to $2.52 following the announcement, the news of regained compliance may attract more investor interest, potentially laying the groundwork for future price recovery.
See More
374Water Secures $850K PFAS Project with St. Cloud City
- Project Approval: 374Water has secured an $850K PFAS waste treatment project with the City of St. Cloud, highlighting the company's technological strength in addressing hazardous substances, which is expected to enhance its market share and brand influence.
- Technology Application: The project will utilize 374Water's mobile AirSCWO 1 system to eliminate PFAS in undigested and post-thermal hydrolysis digested biosolids, showcasing its efficiency and reliability in waste treatment.
- Public Partnership: Funded by the Minnesota Environment and Natural Resources Trust Fund, this project underscores the state government's commitment to clean drinking water initiatives, allowing 374Water to enhance its influence in the public sector.
- Future Outlook: Set to commence in April 2026, this project will demonstrate the effectiveness of 374Water's PFAS treatment technology, further driving the company's strategic development in the environmental sector.
See More
Ultragenyx Shares Plunge 42% Following Phase 3 Study Failures for Setrusumab
- Stock Plunge: Ultragenyx Pharmaceutical's shares fell sharply by 42% to $19.84 on Monday, primarily due to the failure of its Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta, leading to a significant decline in market confidence.
- Clinical Trial Failure: The results from Mereo BioPharma and Ultragenyx indicated that setrusumab did not achieve statistical significance in reducing the annualized clinical fracture rate, which not only impacts the company's short-term financial performance but may also have long-term negative implications for its future R&D investments and market competitiveness.
- Severe Market Reaction: The disappointing trial results raised investor concerns about Ultragenyx's future prospects, resulting in a substantial decrease in its market capitalization, reflecting the high sensitivity of investors to the success or failure of clinical trials in the biopharmaceutical sector.
- Industry Impact: Ultragenyx's failure could have a ripple effect across the biopharmaceutical industry, particularly in the bone metabolism disease space, as investors may adopt a more cautious approach towards similar product developments, potentially affecting financing and R&D strategies of related companies.
See More
374Water Appoints Charles Weiser as CFO to Enhance Strategic Development
- New Board Member: 374Water has appointed Charles Weiser to its Board, whose extensive experience in finance and strategic planning is expected to support the commercialization of the AirSCWO technology, thereby enhancing the company's competitiveness in the waste management market.
- Financial Expertise: As CFO of Alonti Catering Kitchens, Weiser oversaw finance and strategic planning, which is anticipated to strengthen 374Water's financial management capabilities and facilitate sustainable growth for the company.
- Strengthened Shareholder Relations: This appointment is linked to a working agreement with the company's largest shareholder, aiming to establish a solid governance foundation for the next phase of commercialization initiatives, thereby enhancing shareholder trust.
- Long-term Value Creation: Weiser expressed excitement about serving shareholders, indicating confidence in the company's future development, which may attract more investor interest in 374Water's long-term growth potential.
See More
374Water Partners with CRWPCF to Address PFAS Waste Management
- Project Launch: 374Water is partnering with the Cedar Rapids Water Pollution Control Facility and Brown and Caldwell to initiate a PFAS waste treatment project in early Q1 2026, aiming to effectively destroy contaminants to meet long-term regulatory compliance.
- Technology Advantage: The AirSCWO technology from 374Water has demonstrated its effectiveness and scalability in treating solid and liquid wastes, which is expected to provide Cedar Rapids with a uniquely differentiated solution, thereby enhancing its waste management standards.
- Environmental Impact Assessment: The project will validate treatment results through an independent third-party laboratory, with results anticipated by the end of Q1 or early Q2 2026, assisting in evaluating the effectiveness of PFAS contamination mitigation.
- Industry Leadership: 374Water is committed to innovative waste treatment solutions that promote a greener future, and this collaboration is expected to further solidify its leadership position in the industrial and municipal markets.
See More
374Water Regains Nasdaq Compliance with Minimum Bid Price Requirement
- Compliance Restoration: 374Water has received notification from Nasdaq confirming its compliance with the minimum bid price requirement, indicating that the company's compliance issues are resolved, allowing its stock to continue trading on the Nasdaq Capital Market.
- Price Achievement: The company successfully maintained a closing bid price of $1.00 or more for at least 10 consecutive trading days as of January 9, 2026, meeting Nasdaq's listing rules and avoiding potential delisting risks.
- Historical Context: Previously, 374Water received a notification on January 15, 2025, for failing to maintain the minimum bid price over 30 consecutive trading days, and this restoration signifies the stabilization of the company's stock price.
- Market Impact: This compliance restoration not only boosts investor confidence but may also attract more institutional investors, further enhancing the company's market performance and financing capabilities.
See More
374Water (SCWO) Regains Nasdaq Compliance with 10-Day Bid Price Above $1
- Compliance Regained: 374Water announced it has regained compliance with Nasdaq's minimum bid price requirement, as its shares maintained a closing bid price above $1.00 for 10 consecutive trading days, indicating stability and market confidence.
- Continued Trading: Nasdaq confirmed the company meets Listing Rule 5550(a)(2) and has closed the matter, ensuring that SCWO shares will continue trading on the Nasdaq Capital Market, which enhances investor confidence in its future performance.
- Historical Context: 374Water was previously notified in January 2025 for non-compliance after its shares traded below $1.00 for 30 consecutive business days, and regaining compliance marks a significant recovery for the company in the market.
- Market Reaction: Despite SCWO's stock price dropping 2.32% to $2.52 following the announcement, the news of regained compliance may attract more investor interest, potentially laying the groundwork for future price recovery.
See More
374Water Secures $850K PFAS Project with St. Cloud City
- Project Approval: 374Water has secured an $850K PFAS waste treatment project with the City of St. Cloud, highlighting the company's technological strength in addressing hazardous substances, which is expected to enhance its market share and brand influence.
- Technology Application: The project will utilize 374Water's mobile AirSCWO 1 system to eliminate PFAS in undigested and post-thermal hydrolysis digested biosolids, showcasing its efficiency and reliability in waste treatment.
- Public Partnership: Funded by the Minnesota Environment and Natural Resources Trust Fund, this project underscores the state government's commitment to clean drinking water initiatives, allowing 374Water to enhance its influence in the public sector.
- Future Outlook: Set to commence in April 2026, this project will demonstrate the effectiveness of 374Water's PFAS treatment technology, further driving the company's strategic development in the environmental sector.
See More
Ultragenyx Shares Plunge 42% Following Phase 3 Study Failures for Setrusumab
- Stock Plunge: Ultragenyx Pharmaceutical's shares fell sharply by 42% to $19.84 on Monday, primarily due to the failure of its Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta, leading to a significant decline in market confidence.
- Clinical Trial Failure: The results from Mereo BioPharma and Ultragenyx indicated that setrusumab did not achieve statistical significance in reducing the annualized clinical fracture rate, which not only impacts the company's short-term financial performance but may also have long-term negative implications for its future R&D investments and market competitiveness.
- Severe Market Reaction: The disappointing trial results raised investor concerns about Ultragenyx's future prospects, resulting in a substantial decrease in its market capitalization, reflecting the high sensitivity of investors to the success or failure of clinical trials in the biopharmaceutical sector.
- Industry Impact: Ultragenyx's failure could have a ripple effect across the biopharmaceutical industry, particularly in the bone metabolism disease space, as investors may adopt a more cautious approach towards similar product developments, potentially affecting financing and R&D strategies of related companies.
See More
374Water Appoints Charles Weiser as CFO to Enhance Strategic Development
- New Board Member: 374Water has appointed Charles Weiser to its Board, whose extensive experience in finance and strategic planning is expected to support the commercialization of the AirSCWO technology, thereby enhancing the company's competitiveness in the waste management market.
- Financial Expertise: As CFO of Alonti Catering Kitchens, Weiser oversaw finance and strategic planning, which is anticipated to strengthen 374Water's financial management capabilities and facilitate sustainable growth for the company.
- Strengthened Shareholder Relations: This appointment is linked to a working agreement with the company's largest shareholder, aiming to establish a solid governance foundation for the next phase of commercialization initiatives, thereby enhancing shareholder trust.
- Long-term Value Creation: Weiser expressed excitement about serving shareholders, indicating confidence in the company's future development, which may attract more investor interest in 374Water's long-term growth potential.
See More
374Water Partners with CRWPCF to Address PFAS Waste Management
- Project Launch: 374Water is partnering with the Cedar Rapids Water Pollution Control Facility and Brown and Caldwell to initiate a PFAS waste treatment project in early Q1 2026, aiming to effectively destroy contaminants to meet long-term regulatory compliance.
- Technology Advantage: The AirSCWO technology from 374Water has demonstrated its effectiveness and scalability in treating solid and liquid wastes, which is expected to provide Cedar Rapids with a uniquely differentiated solution, thereby enhancing its waste management standards.
- Environmental Impact Assessment: The project will validate treatment results through an independent third-party laboratory, with results anticipated by the end of Q1 or early Q2 2026, assisting in evaluating the effectiveness of PFAS contamination mitigation.
- Industry Leadership: 374Water is committed to innovative waste treatment solutions that promote a greener future, and this collaboration is expected to further solidify its leadership position in the industrial and municipal markets.
See More
